A Phase 3 interventional study of Eylea (Aflibercept, BAY86-5321) and Laser photocoagulation in Retinopathy of Prematurity (ROP), sponsored by Bayer. Completed at 55 sites in 24 countries. Open to participants aged Up to 13 Months. Per ClinicalTrials.gov, last updated 2025-10-10.
Sponsored by Bayer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.
169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.
This study's enrollment of 100 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.
Browse Retinopathy of Prematurity studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Subject has a condition preventing participation in the study, or performance of study procedures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
Drug: Eylea (Aflibercept, BAY86-5321)
No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
Procedure: Laser photocoagulation
Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
Treatment administered in 20090. Transpupillary conventional laser ablative therapy
Binocular best-corrected visual acuity in Snellen equivalent
Time frame: At 5 years of age.
Proportion of subjects with ocular AEs and SAEs
AE: adverse event SAE: serious adverse event
Time frame: Up to 5 years of age.
Proportion of subjects with systemic AEs and SAEs
Time frame: Up to 5 years of age.
Proportion of subjects developing unfavorable ocular structural outcome
Unfavorable ocular structural outcome include: retinal detachment, macular dragging, macular fold, retrolental opacity
Time frame: At 1,3 and 5 years of age.
Proportion of subjects with absence of active ROP and unfavorable structural outcomes
Time frame: At 1 year of age.
Best-corrected visual acuity in each eye
Time frame: At 3 and 5 years of age.
Refractive spherical equivalent in each eye
Time frame: At 3 and 5 years of age
Neurodevelopmental outcomes using BSID-III
BSID-III: The Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is a standard series of tests that will assess the development of children in 3 areas: cognition, language, and motor skills. It is recommended to be assessed at screening, 1 year and 2 years of age. The assessment at 2 years of age is mandatory.
Time frame: At 2 years of age
Neurodevelopmental outcomes using WPPSI-IV
WPPSI-IV: The Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition is designed to assess development of older children and is recommended to be performed at 3, 4 and 5 years of age. The assessment at 5 years of age is mandatory. In cases where the WPSSI-IV cannot be used, the Differential Ability Scales II (DAS-II) may be used as an alternative.
Time frame: At 5 years of age
Neurodevelopmental outcomes using VABS-II
VABS-II: Vineland Adaptive Behavior Scales, Second Edition Expanded Interview will be included, which includes 4 areas: Communication, Daily Living skills, Socialization and Motor Skills. It is recommended to be assessed at 2, 3, 4 and 5 years of age. The assessments at 2 years and 5 years of age are mandatory.
Time frame: At 2 and 5 years of age
Proportion of subjects with recurrence of ROP
Time frame: At 3 and 5 years of age.
Proportion of subjects requiring treatment for ROP
Time frame: Up to 5 years of age.
Proportion of subjects requiring ophthalmological treatment
Time frame: Up to 5 years of age.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Mar 2020 to primary completion in Sep 2025, 66 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept